Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16879335 | 0.95 | AR (0.65) | ARPGR | |
| SCHEMBL16879063 | 0.95 | AR (0.65) | ARPGR | |
| SCHEMBL4025626 | 0.91 | AR (0.68) | ARPGR | |
| SCHEMBL16879351 | 0.91 | AR (0.61) | ARPGR | |
| SCHEMBL16879322 | 0.91 | AR (0.61) | ARPGR | |
| SCHEMBL16879043 | 0.91 | AR (0.60) | ARPGR | |
| SCHEMBL18186677 | 0.91 | AR (0.60) | ARPGR | |
| SCHEMBL18186676 | 0.91 | AR (0.60) | ARPGR | |
| SCHEMBL18186652 | 0.89 | AR (0.61) | ARPGR | |
| SCHEMBL16879044 | 0.89 | AR (0.58) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2419422-B1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA SAS (FR) | 2014-10-15 | — | — | EP | disclosed |
| US-8624037-B2 | Imidazolidine-2,4-dione derivatives and use thereof as a medicament | IPSEN PHARMA S.A.S. (FR) | 2014-01-07 | — | — | US | disclosed |
| US-20120095068-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2419422-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010119194-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | IPSEN PHARMA S.A.S. (FR) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095068-A1 | IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AND USE THEREOF AS A MEDICAMENT | MKI67, CCNI, CCNA1 | AR 2479/4885PGR 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.